Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations-Reference-Cited by-同舟云学术

Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations

Published:2019-11-15 Issue:4 Volume:34 Page:1075-1089
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Austin Rebecca J.,Straube Jasmin,Bruedigam Claudia,Pali Gabor,Jacquelin Sebastien,Vu Therese,Green Joanne,Gräsel Julius,Lansink Lianne,Cooper Leanne,Lee Shin-Jye,Chen Nien-Tsu,Lee Chung-Wei,Haque Ashraful,Heidel Florian H.,D’Andrea Richard,Hill Geoff R.,Mullally Ann,Milsom Michael D.,Bywater Megan,Lane Steven W.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0638-y.pdf

Reference59 articles.

1. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108:3128–34.

2. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA. 2006;103:6224–9.

3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.

4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.

5. Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New Engl J Med. 2005;352:1779–90.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-1β, JAK2V617F mutation and inflammation in MPNs;Blood Advances;2024-08-15

2. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F–positive myeloproliferative neoplasms;Blood;2024-06-13

3. Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms;Frontiers in Immunology;2024-05-07

4. Gadd45g insufficiency drives the pathogenesis of myeloproliferative neoplasms;Nature Communications;2024-04-06

5. Monocytes in allo-HSCT with aged donors secrete IL-1/IL-6/TNF to increase the risk of GVHD and damage the aged HSCs;iScience;2024-03